EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations

Michele Carbone, Michael Minaai, Muaiad Kittaneh, Thomas Krausz, Markku M Miettinen, Qiang Pan Hammarström, Lennart Hammarström, Hassan Abolhassani, Ian Pagano, Ronghui Xu, Flavia Novelli, Giovanni Gaudino und 6 weitere

Journal of Thoracic Oncology · 2025-11 · 20 (11) · 1683-1698

DOI: 10.1016/j.jtho.2025.06.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Oncology, 2025-11. Verfasst von Michele Carbone und 17 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, Hawaii. Electronic address: mcarbone@cc.hawaii.edu. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Tumor Suppressor Proteins, Germ-Line Mutation, Mesothelioma. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, NIH National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Mesothelioma is frequent among carriers of inactivating heterozygous germline BAP1 mutations (BAP1+/-). We studied whether the natural history and the pathology of mesotheliomas in BAP1+/- carriers differed from sporadic, not genetically related, mesotheliomas. METHODS: During 1999 to 2024, we studied 47 families carrying BAP1+/- transmitted in a Mendelian fashion. We characterized these mutations, collected family history, clinical records, prepared family pedigrees, and diagnosed their mesotheliomas. RESULTS: We identified 34 different germline inactivating mutations. Among 238 BAP1+/- carriers aged 27 to 81 years, 84 were diagnosed with mesothelioma (35%) and one of 84 had evidence of asbestos exposure. No mesothelioma was recorded among 123 siblings, first- or second-degree relatives who did not inherit BAP1+/- (p < 0.0001). The 84 patients with BAP1+/- developed mesothelioma at a relatively young age; 45.2% developed multiple cancers. Patients with BAP1+/- had a florid, diffuse mesothelial hyperplasia often present in both pleural cavities, peritoneum and pericardium. Thoracoscopy and laparoscopy results revealed several multicavity approximately 1 to 3 mm whitish flat lesions, but imaging result was usually negative for cancer. Histology results revealed epithelioid cells lacking BAP1 nuclear staining arranged in tubulopapillary and trabecular architectures, focally invading submesothelial adipose tissue. These findings may lead to the diagnosis of stage IV metastatic mesothelioma. However, we found that these tumors remain indolent for years, and, at this early stage, patients do not require aggressive therapy. We refer to these tumors as "low-grade-germline-mutant-BAP1-associated-mesotheliomas, L-BAM" to distinguish them from aggressive, therapy-resistant, sporadic mesotheliomas. For the 1/3 of patients who developed lesions visible by imaging, surgery, chemotherapy, or a combination of both led to survival of several years, and some were cured. Deep invasion by mesothelioma cells with a solid architecture is rare: these cases have poor survival. CONCLUSIONS: Compared with sporadic mesotheliomas, mesotheliomas developing in BAP1+/- carriers are a different disease, biologically, histologically, and clinically; these patients require a tailored clinical approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseTumor Suppressor ProteinsGerm-Line MutationMesotheliomaLung NeoplasmsHumansMaleAgedMiddle AgedAdultFemaleAged, 80 and overPhenotypeMesothelioma, MalignantPedigreeHeterozygotePrognosis

Stichwörter der Autor:innen

BAP1DiagnosisMesotheliomaPrognosis

Substanzen

Ubiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, Hawaii. Electronic address: mcarbone@cc.hawaii.edu.
  • Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Drug Development Service, ICON Clinical Research, Chicago, Illinois.
  • Department of Pathology, University of Chicago, Chicago, Illinois.
  • Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS
  • NIH National Cancer Institute
  • US Department of Defense
  • National Institute of Environmental Health Sciences

Zitieren

APA

Carbone, M., Minaai, M., Kittaneh, M., Krausz, T., Miettinen, M. M., Pan Hammarström, Q., Hammarström, L., Abolhassani, H., Pagano, I., Xu, R., Novelli, F., Gaudino, G., Pastorino, S., Sarin, K. Y., Ripley, R. T., Pass, H. I., Schrump, D. S., & Yang, H. (2025). Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology, 20(11), 1683-1698. https://doi.org/10.1016/j.jtho.2025.06.020

Vancouver

Carbone M, Minaai M, Kittaneh M, Krausz T, Miettinen MM, Pan Hammarström Q, et al. Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology. 2025;20(11):1683-1698. doi:10.1016/j.jtho.2025.06.020

BibTeX
@article{Carbone2025,
  author = {Carbone, Michele and Minaai, Michael and Kittaneh, Muaiad and Krausz, Thomas and Miettinen, Markku M and Pan Hammarström, Qiang and Hammarström, Lennart and Abolhassani, Hassan and Pagano, Ian and Xu, Ronghui and Novelli, Flavia and Gaudino, Giovanni and Pastorino, Sandra and Sarin, Kavita Y and Ripley, Robert T and Pass, Harvey I and Schrump, David S and Yang, Haining},
  title = {Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  volume = {20},
  number = {11},
  pages = {1683--1698},
  doi = {10.1016/j.jtho.2025.06.020}
}
Kostenlos starten →